Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25357982 | 1.00 | MEN1 (0.46) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL31369660 | 0.92 | ADAM17 (0.45) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL31370137 | 0.92 | ADAM17 (0.46) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL31369786 | 0.91 | MDM2 (0.50) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL25357399 | 0.90 | ADAM17 (0.45) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL25357396 | 0.90 | ADAM17 (0.45) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL31370007 | 0.90 | MDM2 (0.49) | ADAM17MDM4TP53SCN9AMDM2 | |
| SCHEMBL25360978 | 0.90 | SLC17A5 (0.49) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL25360974 | 0.90 | SLC17A5 (0.49) | MEN1RECQLKMT2AADAM17MDM4 | |
| SCHEMBL31210290 | 0.90 | SLC17A5 (0.49) | MEN1RECQLKMT2AADAM17MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | MEN1 1901/4885RECQL 4564/4885KMT2A 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.